ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma